Popular Trials
Monoclonal Antibodies
Barzolvolimab for Chronic Hives
This trial is testing a new medication called barzolvolimab to help people with Chronic Spontaneous Urticaria, a condition that causes persistent hives and itching. The medication works by calming the immune system to reduce these symptoms.
Popular Filters
Trials for Chronic Urticaria Patients
Tyrosine Kinase Inhibitor
Povorcitinib for Chronic Spontaneous Urticaria
This trial is testing a new medication called povorcitinib for adults with a chronic skin condition called CSU. These patients haven't found relief with standard treatments. The medication works by reducing the body's overactive immune response.
Monoclonal Antibodies
Dupilumab for Chronic Hives
This trial is testing a medication called dupilumab in children with chronic spontaneous urticaria (CSU) who do not improve with regular allergy medicines. The study aims to see if dupilumab is safe and how it behaves in the body over several months. Dupilumab helps by blocking proteins that cause inflammation, reducing symptoms. Dupilumab is approved in the United States for the treatment of moderate-to-severe atopic dermatitis in adults and children aged 6 and up, demonstrating rapid and sustained efficacy.
Trials for CSU Patients
Tyrosine Kinase Inhibitor
Povorcitinib for Chronic Spontaneous Urticaria
This trial is testing a new medication called povorcitinib for adults with a chronic skin condition called CSU. These patients haven't found relief with standard treatments. The medication works by reducing the body's overactive immune response.
Monoclonal Antibodies
Dupilumab for Chronic Hives
This trial is testing a medication called dupilumab in children with chronic spontaneous urticaria (CSU) who do not improve with regular allergy medicines. The study aims to see if dupilumab is safe and how it behaves in the body over several months. Dupilumab helps by blocking proteins that cause inflammation, reducing symptoms. Dupilumab is approved in the United States for the treatment of moderate-to-severe atopic dermatitis in adults and children aged 6 and up, demonstrating rapid and sustained efficacy.
Phase 3 Trials
Monoclonal Antibodies
Dupilumab for Chronic Hives
This trial is testing a medication called dupilumab in children with chronic spontaneous urticaria (CSU) who do not improve with regular allergy medicines. The study aims to see if dupilumab is safe and how it behaves in the body over several months. Dupilumab helps by blocking proteins that cause inflammation, reducing symptoms. Dupilumab is approved in the United States for the treatment of moderate-to-severe atopic dermatitis in adults and children aged 6 and up, demonstrating rapid and sustained efficacy.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Long-term Remibrutinib for Chronic Hives
This trial tests remibrutinib, a medication for adults with chronic hives not helped by standard treatments. It aims to see if remibrutinib can reduce symptoms by blocking signals that cause hives. Remibrutinib is a highly selective, oral medication that has shown promising efficacy and safety in treating chronic spontaneous urticaria.
Frequently Asked Questions
Introduction to chronic spontaneous urticaria
What are the top hospitals conducting chronic spontaneous urticaria research?
When it comes to cutting-edge clinical trials for chronic spontaneous urticaria, a condition characterized by recurring hives or welts, Novartis Investigative Sites are leading the way. Located in various cities across the United States, these hospitals have dedicated their efforts to advancing our understanding and treatment of this challenging condition. In Little Rock, Boise, Skokie, Owensboro, and Oklahoma City, Novartis Investigative Sites are currently conducting multiple active clinical trials for chronic spontaneous urticaria. Although they haven't recorded any previous trials specifically focused on this condition yet, their commitment to ongoing research demonstrates their dedication to finding new solutions. These sites provide hope for those living with chronic spontaneous urticaria by offering access to innovative treatments that may alleviate symptoms and improve quality of life. Through these collaborative efforts between medical professionals and patients participating in clinical trials at Novartis Investigative Sites across the country we can anticipate significant advancements in the management of chronic spontaneous urticaria in the near future
Which are the best cities for chronic spontaneous urticaria clinical trials?
When it comes to chronic spontaneous urticaria clinical trials, several cities are at the forefront of research and development. Boise, Idaho leads with 8 active trials that focus on Lirentelimab (AK002), Povorcitinib Dose A, LOU064 (remibrutinib), and other potential treatments. Toronto, Ontario follows closely behind with 7 ongoing studies investigating rilzabrutinib, Dupilumab SAR231893, Arm 3: LOU064 (Open Label), and more. Birmingham, Alabama also shows promise with 6 active trials exploring Lirentelimab (AK002), Povorcitinib Dose A, Arm 3: LOU064 (Open Label), among others. These cities offer individuals suffering from chronic spontaneous urticaria access to cutting-edge clinical trials that may lead to better management options for their condition.
Which are the top treatments for chronic spontaneous urticaria being explored in clinical trials?
Clinical trials are actively investigating various treatments for chronic spontaneous urticaria, a distressing condition characterized by recurring hives. Among the top contenders are:
- Omalizumab: Under exploration in six ongoing clinical trials.
- Rupatadine: Being assessed in four active research studies.
- Benralizumab: Currently tested in three clinical trials.
These treatments offer hope for patients suffering from chronic spontaneous urticaria, as researchers strive to find effective solutions to alleviate symptoms and improve quality of life.
What are the most recent clinical trials for chronic spontaneous urticaria?
Exciting advancements are underway in the field of chronic spontaneous urticaria, with recent clinical trials presenting promising treatment options. Povorcitinib Dose A, a Phase 2 trial for this condition, has shown potential benefits in managing symptoms. Additionally, LOU064 (remibrutinib) is being evaluated in Phase 3 trials and holds promise as a future therapeutic option. Another noteworthy trial involves Lirentelimab (AK002), which has entered Phase 2 testing and shows encouraging results thus far. Lastly, Dupilumab has completed Phase 3 trials and offers hope for individuals suffering from chronic spontaneous urticaria. With these exciting developments on the horizon, there is renewed optimism for improved management of this challenging condition.
What chronic spontaneous urticaria clinical trials were recently completed?
Recently completed clinical trials have made significant strides in the field of chronic spontaneous urticaria, a condition characterized by recurrent hives. Notably, a trial sponsored by Novartis Pharmaceuticals concluded in August 2021 and focused on evaluating the efficacy of an investigational medication as a potential treatment option for this challenging disorder. These advancements hold promise for individuals living with chronic spontaneous urticaria and highlight ongoing efforts to improve therapeutic options and enhance quality of life for patients affected by this condition.